{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:05:37Z","timestamp":1792418737905,"version":"4.5.0"},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:sec id=\"ab-hoi250071-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Clonal hematopoiesis of indeterminate potential (CHIP), the age-related clonal expansion of hematopoietic cells with acquired preleukemic variants, has been associated with cardiometabolic diseases, including heart failure (HF). However, prior studies have lacked power to examine less common CHIP driver variants and have not investigated potential mediators of the CHIP-HF association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250071-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To test whether specific CHIP subtypes are associated with incident HF and determine the extent to which CHIP-associated comorbidities mediate this association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250071-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This was a UK Biobank prospective population-based cohort study of community-dwelling adults in the UK, with enrollment from 2006 to 2010 and follow-up through 2020. Included were participants with whole-exome sequencing (WES) and without prevalent HF, hematologic malignancy, or other CHIP-associated comorbidities (coronary artery disease [CAD], atrial fibrillation [AF], type 2 diabetes [T2D], or chronic kidney disease [CKD]) at baseline. Study data were analyzed from April through October 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250071-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>\n                      Presence of CHIP and gene-specific CHIP subtypes (\n                      <jats:italic toggle=\"yes\">DNMT3A,<\/jats:italic>\n                      non-\n                      <jats:italic toggle=\"yes\">DNMT3A, TET2, ASXL1, JAK2,<\/jats:italic>\n                      DNA damage repair genes, and spliceosome genes). Mediation analyses examined CHIP-associated comorbidities (CAD, AF, T2D, and CKD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250071-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was incident HF. Cox regression tested associations of CHIP and CHIP subtypes with incident HF, adjusted for age, sex, race, and cardiovascular risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250071-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 417\u202f616 participants (mean [SD] age, 56.1 [8.1] years; 234\u202f868 female [56.2%]), 7183 (1.7%) developed incident HF over a median (IQR) of 11.1 (10.4-11.8) years of follow-up. CHIP was associated with HF risk (adjusted hazard ratio [aHR], 1.27; 95% CI, 1.15-1.40;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), driven by non-\n                      <jats:italic toggle=\"yes\">DNMT3A<\/jats:italic>\n                      subtypes (aHR, 1.52; 95% CI, 1.33-1.75;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001), including associations with\n                      <jats:italic toggle=\"yes\">TET2<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">ASXL1<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      , and spliceosome CHIP.\n                      <jats:italic toggle=\"yes\">DNMT3A<\/jats:italic>\n                      CHIP was more modestly associated with HF (aHR, 1.15; 95% CI, 1.00-1.31;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.04). In mediation analyses, development of CAD, AF, T2D, and\/or CKD collectively accounted for 28.2% of the association (95% CI, 11.6%-45.4%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.001) between non-\n                      <jats:italic toggle=\"yes\">DNMT3A<\/jats:italic>\n                      CHIP and HF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi250071-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>\n                      Results of this cohort study suggest that CHIP, especially non-\n                      <jats:italic toggle=\"yes\">DNMT3A<\/jats:italic>\n                      CHIP, was associated with incident HF. Other CHIP-associated comorbidities explained only a minority of the association between non\n                      <jats:italic toggle=\"yes\">-DNMT3A<\/jats:italic>\n                      CHIP and HF. These findings suggest that CHIP is an HF risk factor and potential therapeutic target.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2025.4603","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T18:30:19Z","timestamp":1762713019000},"page":"126","source":"Crossref","is-referenced-by-count":20,"title":["Clonal Hematopoiesis and Incident Heart Failure"],"prefix":"10.1001","volume":"11","author":[{"given":"Spencer","family":"Flynn","sequence":"first","affiliation":[{"name":"Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts"},{"name":"Department of Medicine, Massachusetts General Hospital, Boston"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Art","family":"Schuermans","sequence":"additional","affiliation":[{"name":"Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts"},{"name":"Faculty of Medicine, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Mesbah","family":"Uddin","sequence":"additional","affiliation":[{"name":"Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Nakao","sequence":"additional","affiliation":[{"name":"Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Viscosi","sequence":"additional","affiliation":[{"name":"Cardiology Division, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Cardiology Division, Massachusetts General Hospital, Boston"},{"name":"Center for Genomic Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Honigberg","sequence":"additional","affiliation":[{"name":"Program in Medical and Population Genetics and Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, Massachusetts"},{"name":"Department of Medicine, Harvard Medical School, Boston, Massachusetts"},{"name":"Cardiology Division, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"26","key":"hoi250071r1","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes.","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi250071r2","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies.","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"18","key":"hoi250071r3","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood.2022018825","article-title":"A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets.","volume":"141","author":"Vlasschaert","year":"2023","journal-title":"Blood"},{"issue":"1","key":"hoi250071r4","doi-asserted-by":"publisher","first-page":"e2353244","DOI":"10.1001\/jamanetworkopen.2023.53244","article-title":"Clonal hematopoiesis and incident heart failure with preserved ejection fraction.","volume":"7","author":"Schuermans","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"hoi250071r5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jacc.2021.04.085","article-title":"Supplemental association of clonal hematopoiesis with incident heart failure.","volume":"78","author":"Yu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi250071r6","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41569-025-01148-9","article-title":"Clonal hematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target.","volume":"22","author":"Schuermans","year":"2025","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"hoi250071r7","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1161\/CIRCRESAHA.125.325489","article-title":"Contributions of noncardiac organ-heart immune crosstalk and somatic mosaicism to heart failure: current knowledge and perspectives.","volume":"136","author":"Kallikourdis","year":"2025","journal-title":"Circ Res"},{"issue":"1","key":"hoi250071r8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2715","article-title":"Clonal hematopoiesis of indeterminate potential: associations with heart failure incidence, clinical parameters and biomarkers.","volume":"25","author":"Shi","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hoi250071r9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease.","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"hoi250071r10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1093\/eurheartj\/ehad670","article-title":"Clonal hematopoiesis of indeterminate potential predicts incident cardiac arrhythmias.","volume":"45","author":"Schuermans","year":"2024","journal-title":"Eur Heart J"},{"issue":"11","key":"hoi250071r11","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.2337\/dc23-0805","article-title":"Clonal hematopoiesis of indeterminate potential (CHIP) and incident type 2 diabetes risk.","volume":"46","author":"Tobias","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"hoi250071r12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41581-023-00778-x","article-title":"Clonal hematopoiesis, aging, and kidney disease.","volume":"20","author":"Vlasschaert","year":"2024","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"hoi250071r13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1053\/j.ajkd.2022.08.014","article-title":"Clonal hematopoiesis of indeterminate potential and kidney function decline in the general population.","volume":"81","author":"Kestenbaum","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"hoi250071r14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jacc.2019.06.007","article-title":"Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week.","volume":"74","author":"Libby","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi250071r15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cardfail.2023.10.024","article-title":"HERMES: effects of ziltivekimab vs placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.","volume":"30","author":"Petrie","year":"2024","journal-title":"J Card Fail"},{"issue":"2","key":"hoi250071r16","doi-asserted-by":"publisher","first-page":"S767","DOI":"10.1016\/j.ekir.2024.11.1354","article-title":"WCN25-888 design of the ZEUS trial: interleukin 6 inhibition with ziltivekimab for cardiovascular protection in chronic kidney disease.","volume":"10","author":"Perkovic","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"9","key":"hoi250071r17","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1038\/s41591-024-03188-z","article-title":"Clonal hematopoiesis, cardiovascular events and treatment benefit in 63?700 individuals from 5 TIMI randomized trials.","volume":"30","author":"Marston","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"hoi250071r18","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/s41588-022-01179-9","article-title":"Single-cell multiomics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation.","volume":"54","author":"Nam","year":"2022","journal-title":"Nat Genet"},{"issue":"4","key":"hoi250071r19","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/EDE.0b013e31821db37e","article-title":"Causal mediation analysis with survival data.","volume":"22","author":"VanderWeele","year":"2011","journal-title":"Epidemiology"},{"issue":"8","key":"hoi250071r20","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41588-022-01121-z","article-title":"Genome-wide analyses of 200?453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.","volume":"54","author":"Kar","year":"2022","journal-title":"Nat Genet"},{"issue":"1","key":"hoi250071r21","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"issue":"10","key":"hoi250071r22","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1161\/ATVBAHA.120.314760","article-title":"Platelet dysfunction and thrombosis in JAK2 V617F-mutated primary myelofibrotic mice.","volume":"40","author":"Matsuura","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"hoi250071r23","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors.","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"15","key":"hoi250071r24","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1182\/blood.2023022260","article-title":"JAK2 V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk.","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"6","key":"hoi250071r25","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jacbts.2019.05.013","article-title":"JAK2 V617F-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure.","volume":"4","author":"Sano","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"20","key":"hoi250071r26","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.jacc.2023.03.401","article-title":"Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease.","volume":"81","author":"Gumuser","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"hoi250071r27","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78136","article-title":"Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations.","volume":"11","author":"Choudhary","year":"2022","journal-title":"Elife"},{"issue":"9","key":"hoi250071r28","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.3324\/haematol.2018.214155","article-title":"Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.","volume":"104","author":"Pollyea","year":"2019","journal-title":"Haematologica"},{"key":"hoi250071r29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1419807","article-title":"The immunobiology of myelodysplastic neoplasms: a mini-review.","volume":"15","author":"Kannan","year":"2024","journal-title":"Front Immunol"},{"issue":"14","key":"hoi250071r30","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2021.02.028","article-title":"Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction.","volume":"77","author":"Pascual-Figal","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hoi250071r31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1161\/CIRCULATIONAHA.122.062126","article-title":"Interleukin-6 receptor polymorphism attenuates clonal hematopoiesis-mediated coronary artery disease risk among 451 180 individuals in the UK Biobank.","volume":"147","author":"Vlasschaert","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"hoi250071r32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2018.3965","article-title":"Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure.","volume":"4","author":"Dorsheimer","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"3","key":"hoi250071r33","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/eurheartj\/ehaa845","article-title":"Clonal hematopoiesis in chronic ischemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.","volume":"42","author":"Assmus","year":"2021","journal-title":"Eur Heart J"},{"issue":"15","key":"hoi250071r34","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1161\/CIRCULATIONAHA.123.064170","article-title":"Clonal hematopoiesis in clinical and experimental heart failure with preserved ejection fraction.","volume":"148","author":"Cochran","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"hoi250071r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115494","article-title":"Sex differences in DNMT3A-mutant clonal hematopoiesis and the effects of estrogen.","volume":"44","author":"Stomper","year":"2025","journal-title":"Cell Rep"},{"issue":"1","key":"hoi250071r36","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41467-023-43003-w","article-title":"DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts.","volume":"15","author":"Shumliakivska","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"hoi250071r37","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/s44161-023-00322-x","article-title":"Cell-intrinsic effects of clonal hematopoiesis in heart failure.","volume":"2","author":"Abplanalp","year":"2023","journal-title":"Nat Cardiovasc Res"},{"issue":"15","key":"hoi250071r38","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.jacc.2025.07.058","article-title":"Clonal hematopoiesis and cardiovascular outcomes in older women.","volume":"86","author":"Ezzat","year":"2025","journal-title":"JACC"},{"issue":"21","key":"hoi250071r39","doi-asserted-by":"publisher","first-page":"11355","DOI":"10.1093\/nar\/gkz911","article-title":"Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns.","volume":"47","author":"Emperle","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"hoi250071r40","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ccr.2014.02.010","article-title":"The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.","volume":"25","author":"Russler-Germain","year":"2014","journal-title":"Cancer Cell"},{"issue":"6","key":"hoi250071r41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.135204","article-title":"TET2-mediated clonal hematopoiesis in nonconditioned mice accelerates age-associated cardiac dysfunction.","volume":"5","author":"Wang","year":"2020","journal-title":"JCI Insight"},{"issue":"22","key":"hoi250071r42","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1161\/CIRCULATIONAHA.124.072909","article-title":"TET2-mutant clonal hematopoiesis promotes heart failure with preserved ejection fraction.","volume":"151","author":"Pandey","year":"2025","journal-title":"Circulation"},{"issue":"18","key":"hoi250071r43","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.123.065597","article-title":"Clonal hematopoiesis of indeterminate potential with loss of TET2 enhances risk for atrial fibrillation through NLRP3 inflammasome activation.","volume":"149","author":"Lin","year":"2024","journal-title":"Circulation"},{"issue":"8","key":"hoi250071r44","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.jacc.2017.12.037","article-title":"TET2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1\u00df\/NLRP3 inflammasome.","volume":"71","author":"Sano","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hoi250071r45","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1001\/jamacardio.2022.0386","article-title":"TET2-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial.","volume":"7","author":"Svensson","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hoi250071r46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/CIRCULATIONAHA.119.044362","article-title":"Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis.","volume":"141","author":"Bick","year":"2020","journal-title":"Circulation"},{"issue":"8067","key":"hoi250071r47","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-025-08871-w","article-title":"Metformin reduces the competitive advantage of DNMT3A R878H HSPCs.","volume":"642","author":"Hosseini","year":"2025","journal-title":"Nature"},{"key":"hoi250071r48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.08.025","article-title":"Colchicine and longitudinal dynamics of clonal hematopoiesis: an exploratory substudy of the LoDoCo2 trial.","author":"Mohammadnia","journal-title":"J Am Coll Cardiol"},{"issue":"7831","key":"hoi250071r49","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal hematopoiesis in 97?691 whole genomes.","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"issue":"9","key":"hoi250071r51","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/aje\/kwx246","article-title":"Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population.","volume":"186","author":"Fry","year":"2017","journal-title":"Am J Epidemiol"},{"key":"hoi250071r50","doi-asserted-by":"crossref","unstructured":"Corty? R, Pershad? Y, Vlasschaert? C, . Detection of clonal hematopoiesis of indeterminate potential via genome or exome sequencing profoundly underestimates disease associations.? medRxiv. 2025:2025.2008.2011.25333294. doi:10.1101\/2025.08.11.25333294","DOI":"10.1101\/2025.08.11.25333294"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2841165\/jamacardiology_flynn_2025_oi_250071_1770405043.87126.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:00:28Z","timestamp":1770825628000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2841165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.4603","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}